Marché des tests moléculaires au point de service (à l’aide du NAAT) au Moyen-Orient – ​​Tendances et prévisions de l’industrie jusqu’en 2028

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché des tests moléculaires au point de service (à l’aide du NAAT) au Moyen-Orient – ​​Tendances et prévisions de l’industrie jusqu’en 2028

  • Medical Devices
  • Publish Reports
  • Aug 2022
  • MEA
  • 350 Pages
  • Nombre de tableaux : 184
  • Nombre de figures : 47

Marché des tests moléculaires au point de service (utilisant NAAT) au Moyen-Orient, par produit (instruments et consommables et réactifs), indication (tests d'infections respiratoires, tests d'infections sexuellement transmissibles (IST) , tests d'infections du tractus gastro-intestinal et autres), utilisateur final (laboratoires, hôpitaux, cliniques, centres ambulatoires, soins à domicile, établissements de vie assistée et autres), mode de test (tests sur ordonnance et tests en vente libre), canal de distribution (pharmacie hospitalière, pharmacie de détail et pharmacie en ligne) - Tendances et prévisions de l'industrie jusqu'en 2028.

Marché des tests moléculaires au point de service (à l'aide du NAAT) au Moyen-Orient

Analyse et perspectives du marché des tests moléculaires au point de service (à l'aide du NAAT) au Moyen-Orient

Le marché des tests moléculaires au point de service (utilisant le NAAT) au Moyen-Orient devrait croître en raison de l’amélioration des installations et des infrastructures de soins de santé et de l’adoption de tests de fin de soins dans les hôpitaux, les laboratoires et les cliniques, ce qui peut stimuler le développement du marché. Les autres facteurs qui devraient propulser la croissance du marché des tests moléculaires au point de service (utilisant le NAAT) comprennent la prévalence croissante des maladies infectieuses.

D'autres facteurs, tels que le manque de professionnels qualifiés et le coût élevé des tests moléculaires au point d'intervention personnalisés (utilisant le NAAT), freinent la croissance du marché des tests moléculaires au point d'intervention (utilisant le NAAT) au Moyen-Orient. D'autre part, l'augmentation des dépenses de santé et l'émergence de pays dotés d'hôpitaux développés constituent une opportunité pour développer le marché des tests moléculaires au point d'intervention (utilisant le NAAT) au Moyen-Orient.

Data Bridge Market Research analyse que le marché des tests moléculaires au point de service (utilisant NAAT) au Moyen-Orient connaîtra un TCAC de 7,4 % de 2021 à 2028.

Rapport métrique

Détails

Période de prévision

2021 à 2028

Année de base

2020

Années historiques

2019

Unités quantitatives

Chiffre d'affaires en millions USD, prix en USD

Segments couverts

Par produit (instruments, consommables et réactifs), indication (tests d'infections respiratoires, tests d'infections sexuellement transmissibles (IST), tests d'infections du tractus gastro-intestinal et autres), utilisateur final (laboratoires, hôpitaux, cliniques, centres ambulatoires, soins à domicile, résidences pour personnes âgées assistées et autres), mode de test (tests sur ordonnance et tests en vente libre), canal de distribution (pharmacie hospitalière, pharmacie de détail et pharmacie en ligne)

Pays couverts

Arabie saoudite, Émirats arabes unis, Israël, Égypte et le reste du Moyen-Orient

Acteurs du marché couverts

SD Biosensor, Inc., Abbott, F.Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc, Meridian Bioscience, BD, Biomérieux Sa, Qiagen, Quidel Corporation, Bio-Rad Laboratories, Inc., GenMark Diagnostics, Seegene Inc. et Grifols SA, entre autres

Définition du marché des tests moléculaires au point de service (à l'aide du NAAT) au Moyen-Orient

POCT is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30cm x 30cm. These instruments are essentially used in molecularly detecting various disorders such as HIV, HPV, and respiratory disease through NAAT technology. NAAT is Nucleic Acid Amplification Techniques that allow the identification of pathogenic organisms by detecting their DNA or RNA.

In the worldwide pandemic, attempt to synergize the sensitivity of NAATs and the ease of use of POCT assays, miniaturized NAAT-based POCT devices and assays were devised for faster screening and diagnosis of COVID-19, which also propelled the growth of the market.

Middle East Molecular Point of Care Testing (using NAAT) Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

  • INCREASE IN PREVALENCE OF CHRONIC DISEASES

It is a common fact that health degeneration starts with an increase in age. As the rate of chronic disease grows with time, the factors associated with the disease rates also increase. The high number of obese/ overweight population also has increased the prevalence of chronic diseases in various regions across the globe. The rise in the number of chronic diseases similar to HPV, STI, and TB, among more, has led to people opting for NAAT-based point-of-care and products for testing. Therefore, this will drive the growth of the Middle East molecular point of care testing (using NAAT) market in the coming years.

  • IMPROVEMENT IN DIAGNOSIS-SEEKING RATE

With the increase in the successful diagnosis of chronic diseases, including cancer, anemia, type 2 diabetes, and others, the improved health care professionals provide regular training sessions for the professionals for conducting tests in account for the improvement of diagnosis rate in the region. With the increase in the burden of diseases, the diagnosis rate is also increasing. With the advancements in the diagnosis, the rate is also growing for people going through the diagnosis.

  • RISE IN PREFERENCE FOR HOMECARE TESTING

Home healthcare preferences make clinical information available at the right place and time. It will also help in reducing error and increasing safety with ensured quality. They also help elders in the case of a medical emergency. Many strategic changes have been made in health care to address point-of-care testing benefits. As per the World Health Organization (WHO), the number of people aged 65 and above is expected to rise from an estimated 524 million in 2010 to approximately 1.5 billion in 2050, with developed countries accounting for the majority of the increase.

Opportunities

  • STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

An increase in the burden of chronic and non-chronic disease globally coupled with the rise in the geriatric population in Africa and Asia has created more demand for the development of new kits and solutions for molecular point-of-care testing with better efficacy and less time consumption. To provide diagnosis and screening in this region, the players in the market undergo partnership and agreement with each other to provide quality care through kits and instruments to the Middle East population.

  • RisE IN Healthcare Expenditure

Increasing healthcare expenditure and infrastructure can help patients take hassle-free advanced treatment to receive better diagnoses, procedures, and treatment for fast recovery. Point-of-care testing devices are beneficial for detecting various diseases and supporting treatment plans using POC software and solutions. Healthcare spending comprises out-of-pocket payments (people paying for their care), government expenditure, and sources including health insurance and activities by non-governmental organizations.

Restraints/Challenges

  • HIGH COST OF PRODUCTS

The point-of-care testing products require a substantial considerable cost for the development process. As the concept needs to be locked down, the materials must be sourced, and it is essential to consider lead times. Additionally, the process is time-consuming as the device design needs sufficient time to fully mature before bringing to the market for use.

  • LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES

When compared with the results of laboratory testing standards, the NAAT testing results differ. Laboratory testing is more advanced, follows the process, protocol, and science for laboratory testing, and fully integrates with the technology necessary to analyze, validate, and document effects accurately. However, POCT/NAAT is undoubtedly associated with a lack of precise results. Molecular POCT cannot complete the standardization, and other critical criteria cannot achieve the standardization and different essential standards. It is a significant challenge for the Middle East molecular point of care testing market. The PoC tests might sometimes provide erroneous results and suffers test results variability.

Post COVID-19 Impact on Middle East Molecular Point of Care Testing (using NAAT) Market

La COVID-19 a eu un impact significatif sur le marché des tests moléculaires au point de service (utilisant le NAAT). La COVID-19 a eu un impact positif sur le prix et la demande de produits de tests moléculaires au point de service (utilisant le NAAT) à un niveau plus élevé en raison des ventes en ligne progressives et des avancées technologiques. L'épidémie de la pandémie de COVID-19 a eu un impact positif sur la croissance du marché en raison de la demande accrue de tests moléculaires au point de service (utilisant le NAAT), en particulier dans divers hôpitaux. La priorité actuelle dans la plupart des hôpitaux est donnée aux traitements COVID-19 car la flambée des cas de COVID-19 est toujours persistante, ce qui augmente également l'utilisation des tests moléculaires au point de service (utilisant le NAAT). De plus, de nombreux gouvernements internationaux et organisations de soins de santé ont soutenu l'approvisionnement de ces produits en raison de leur haute priorité dans les cas cruciaux.

Développements récents

  • En novembre 2021, F.Hoffmann-La Roche Ltd a annoncé que Roche se classait parmi les trois entreprises de soins de santé les plus durables dans les indices de durabilité Dow Jones pour la treizième année consécutive. Cela a augmenté la capacité d'activité et l'expansion des activités au cours de la période de prévision
  • En octobre 2021, Thermo Fisher Scientific Corporation a reçu l'approbation de la FDA pour le test TaqMan COVId-19 SARS-COV molecular Assay. Cela a augmenté le portefeuille de produits de l'entreprise et a contribué au chiffre d'affaires de l'entreprise au cours de la période de prévision

Portée du marché des tests moléculaires au point de service (à l'aide du NAAT) au Moyen-Orient

Le marché des tests moléculaires au point de service (utilisant NAAT) au Moyen-Orient est classé en cinq segments notables en fonction du produit, de l'indication, de l'utilisateur final, du mode de test et du canal de distribution. La croissance de ces segments aidera à analyser les segments de croissance du marché dans les industries et fournira aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour les aider à prendre des décisions stratégiques pour identifier les principales applications du marché.

Produit

  • Instruments
  • Consommables et réactifs

En fonction du produit, le marché des tests moléculaires au point de service (utilisant NAAT) au Moyen-Orient est segmenté en instruments, consommables et réactifs.

Indication

  • Test de dépistage des infections sexuellement transmissibles (IST)
  • Test d'infection respiratoire
  • Test d'infection du tractus gastro-intestinal
  • Autres

Sur la base des indications, le marché des tests moléculaires au point de service du Moyen-Orient (utilisant le NAAT) est segmenté en tests d'infections sexuellement transmissibles (IST), tests d'infections respiratoires, tests d'infections du tractus gastro-intestinal et autres.

Utilisateur final

  • Laboratoires
  • Hôpitaux
  • Cliniques
  • Centres ambulatoires
  • Soins à domicile
  • Résidences pour personnes âgées assistées
  • Autres

En fonction de l'utilisateur final, le marché des tests moléculaires au point de service (utilisant NAAT) du Moyen-Orient est segmenté en laboratoires, hôpitaux, cliniques, centres ambulatoires, soins à domicile, établissements de vie assistée et autres.

Mode de test

  • Tests sur ordonnance
  • Tests en vente libre

En fonction du mode de test, le marché des tests moléculaires au point de service (utilisant NAAT) au Moyen-Orient est segmenté en tests sur ordonnance et tests en vente libre .

Canal de distribution

  • Pharmacie de l'hôpital
  • Pharmacie de détail
  • Pharmacie en ligne

Marché des tests moléculaires au point de service (à l'aide du NAAT)

En fonction du canal de distribution, le marché des tests moléculaires au point de service (utilisant NAAT) au Moyen-Orient est segmenté en pharmacie hospitalière, pharmacie de détail et pharmacie en ligne.

Analyse/perspectives régionales du marché des tests moléculaires au point de service (à l'aide du NAAT) au Moyen-Orient

Le marché des tests moléculaires au point de service (à l'aide d'ANAT) est analysé au Moyen-Orient. Des informations sur la taille du marché et les tendances sont fournies en fonction du produit, de l'indication, de l'utilisateur final, du mode de test et du canal de distribution.

Le rapport sur le marché des tests moléculaires au point de service (utilisant NAAT) au Moyen-Orient couvre l'Arabie saoudite, les Émirats arabes unis, Israël, l'Égypte et le reste du Moyen-Orient.

L'Arabie saoudite domine le marché des tests moléculaires au point de service (utilisant le NAAT) au Moyen-Orient avec un TCAC d'environ 9,2 % en termes de part de marché et de chiffre d'affaires. Elle continuera à accroître sa domination au cours de la période de prévision. Cela est dû à la prévalence croissante des maladies infectieuses et chroniques et à l'adoption par les hôpitaux des tests au point de service.

Analyse du paysage concurrentiel et des parts de marché des tests moléculaires au point de service (à l'aide du NAAT) au Moyen-Orient

Le paysage concurrentiel du marché des tests moléculaires au point de service (utilisant NAAT) au Moyen-Orient fournit des détails sur le concurrent. Les composants inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence au Moyen-Orient, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les directives réglementaires, l'analyse de la marque, les approbations de produits, la charge utile du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises concernant le marché des tests moléculaires au point de service (utilisant NAAT) au Moyen-Orient.

Certains des principaux acteurs opérant sur le marché des tests moléculaires au point de service (utilisant NAAT) au Moyen-Orient sont SD Biosensor, Inc., Abbott, F.Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc, Meridian Bioscience, BD, Biomérieux Sa, Qiagen, Quidel Corporation, Bio-Rad Laboratories, Inc., GenMark Diagnostics, Seegene Inc. et Grifols SA, entre autres.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 DISTRIBUTION CHANNEL LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES

4.3.1 CEPHEID

4.3.2 THERMO FISHER SCIENTIFIC INC.

4.3.3 HOLOGIC, INC.

4.3.4 BD

4.3.5 F. HOFFMANN-LA ROCHE LTD

4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY

4.5 DISTRIBUTORS

4.5.1 NORTH AMERICA

4.5.2 EUROPE

4.5.3 SOUTH ASIA

4.5.4 SOUTH EAST ASIA

4.5.5 MIDDLE EAST

4.5.6 AFRICA

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES

6.1.2 IMPROVING DIAGNOSIS SEEKING RATE

6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS

6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE

6.1.5 RISING PREFERENCE FOR HOMECARE TESTING

6.2 RESTRAINTS

6.2.1 PRODUCT RECALLS

6.2.2 HIGH COSTS OF PRODUCTS

6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

6.3.2 RISING HEALTHCARE EXPENDITURE

6.3.3 PANDEMIC OUTBREAK OF COVID-19

6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS

6.4 CHALLENGES

6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES

6.4.2 LACK OF ACCESSIBILITY

7 IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY CHAIN

7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19

7.5 CONCLUSION:

8 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT

8.1 OVERVIEW

8.2 CONSUMABLES & REAGENTS

8.3 INSTRUMENTS

8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)

8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)

9 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION

9.1 OVERVIEW

9.2 RESPIRATORY INFECTIONS TESTING

9.2.1 COVID-19

9.2.2 FLU B

9.2.3 FLU A

9.2.4 RSV

9.2.5 TUBERCULOSIS

9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)

9.2.7 OTHERS

9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING

9.3.1 TV

9.3.2 CT

9.3.3 NG

9.3.4 HPV

9.3.5 HSV

9.3.6 MG

9.3.7 UU

9.3.8 MH

9.3.9 OTHERS

9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING

9.4.1 GROUP B STREPTOCOCCUS

9.4.2 SHIGA TOXIN

9.4.3 H. PYLORI

9.5 OTHERS

10 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER

10.1 OVERVIEW

10.2 LABORATORIES

10.2.1 POLYMERASE CHAIN REACTION

10.2.2 ISOTHERMAL AMPLIFICATION

10.3 HOSPITAL

10.3.1 POLYMERASE CHAIN REACTION

10.3.2 ISOTHERMAL AMPLIFICATION

10.4 CLINICS

10.4.1 POLYMERASE CHAIN REACTION

10.4.2 ISOTHERMAL AMPLIFICATION

10.5 AMBULATORY CENTER

10.5.1 POLYMERASE CHAIN REACTION

10.5.2 ISOTHERMAL AMPLIFICATION

10.6 HOMECARE

10.6.1 POLYMERASE CHAIN REACTION

10.6.2 ISOTHERMAL AMPLIFICATION

10.7 ASSISTED LIVING FACILITIES

10.7.1 POLYMERASE CHAIN REACTION

10.7.2 ISOTHERMAL AMPLIFICATION

10.8 OTHERS

11 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING

11.1 OVERVIEW

11.2 PRESCRIPTION-BASED TESTING

11.3 OTC TESTING

12 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACY

12.3 RETAIL PHARMACY

12.4 ONLINE PHARMACY

13 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION

13.1 MIDDLE EAST

13.1.1 SAUDI ARABIA

13.1.2 U.A.E

13.1.3 ISRAEL

13.1.4 EGYPT

13.1.5 REST OF MIDDLE EAST

13.2 AFRICA

13.2.1 SOUTH AFRICA

13.2.2 KENYA

13.2.3 NIGERIA

13.2.4 REST OF AFRICA

14 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 DANAHER

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 THERMO FISHER SCIENTIFIC INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 BD

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 F.HOFFMANN-LA-ROCHE LTD.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 ABBOTT

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 BINX HEALTH, INC.

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 BIOMERIEUX SA

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 CO-DIAGNOSTICS, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

16.9 GENMARK DIAGNOSTICS, INC

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 GRIFOLS, S.A.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 LUCIRA HEALTH INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENTS

16.12 MERIDIAN BIOSCIENCE

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENTS

16.13 QUANTUMDX GROUP LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 QUIDEL CORPORATION

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 SD BIOSENSOR, INC.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENT

16.17 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENT

16.18 WONDFO

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

Liste des tableaux

TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)

TABLE 7 DISTRIBUTORS ACROSS NORTH AMERICA

TABLE 8 DISTRIBUTORS ACROSS EUROPE

TABLE 9 DISTRIBUTORS ACROSS SOUTH ASIA

TABLE 10 DISTRIBUTORS ACROSS SOUTH EAST ASIA

TABLE 11 DISTRIBUTORS ACROSS MIDDLE EAST

TABLE 12 DISTRIBUTORS ACROSS AFRICA

TABLE 13 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA RETAIL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA ONLINE PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 53 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 55 MIDDLE EAST HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 58 MIDDLE EAST HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 59 MIDDLE EAST ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 60 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 61 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 62 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 63 SAUDI ARABIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 64 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 65 SAUDI ARABIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 66 SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 67 SAUDI ARABIAGASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 68 SAUDI ARABIAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 69 SAUDI ARABIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 70 SAUDI ARABIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 71 SAUDI ARABIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 72 SAUDI ARABIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 73 SAUDI ARABIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 74 SAUDI ARABIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 75 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 76 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 77 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 78 U.A.E INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 79 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 80 U.A.E RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 81 U.A.E SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 82 U.A.E GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 83 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 84 U.A.E LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 85 U.A.E HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 86 U.A.E CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 87 U.A.E AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 88 U.A.E HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 89 U.A.E ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 90 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 91 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 92 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 93 ISRAEL INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 94 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 95 ISRAEL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 96 ISRAEL SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 97 ISRAEL GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 98 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 ISRAEL LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 100 ISRAEL HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 101 ISRAEL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 102 ISRAEL AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 103 ISRAEL HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 104 ISRAEL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 105 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 106 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 107 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 108 EGYPT INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 109 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 110 EGYPT RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 111 EGYPT SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 112 EGYPT GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 113 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 114 EGYPT LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 115 EGYPT HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 116 EGYPT CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 117 EGYPT AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 118 EGYPT HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 119 EGYPT ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 120 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 121 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 122 REST OF MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 123 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 124 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 125 AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 126 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 127 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 128 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 129 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 130 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 131 AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 132 AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 133 AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 134 AFRICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 135 AFRICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 136 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 137 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 138 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 139 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 140 SOUTH AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 141 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 142 SOUTH AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 143 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 144 SOUTH AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 145 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 146 SOUTH AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 147 SOUTH AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 148 SOUTH AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 149 SOUTH AFRICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 150 SOUTH AFRICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 151 SOUTH AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 152 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 153 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 154 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 155 KENYA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 156 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 157 KENYA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 158 KENYA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 159 KENYA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 160 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 161 KENYA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 162 KENYA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 163 KENYA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 164 KENYA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 165 KENYA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 166 KENYA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 167 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 168 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 169 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 170 NIGERIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 171 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 172 NIGERIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 173 NIGERIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 174 NIGERIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 175 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 176 NIGERIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 177 NIGERIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 178 NIGERIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 179 NIGERIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 180 NIGERIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 181 NIGERIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 182 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 183 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 184 REST OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

Liste des figures

FIGURE 1 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING

FIGURE 8 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID

FIGURE 11 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS-SEEKING RATE ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD

FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

FIGURE 16 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016

FIGURE 17 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020

FIGURE 18 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)

FIGURE 19 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 20 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 21 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020

FIGURE 22 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 23 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 24 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 25 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020

FIGURE 26 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 27 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)

FIGURE 28 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020

FIGURE 30 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)

FIGURE 31 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)

FIGURE 32 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE

FIGURE 33 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 34 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 35 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 36 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 37 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 38 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 39 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 40 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 41 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 42 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 43 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 44 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 45 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 46 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 47 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The Middle East Molecular Point of Care Testing (using NAAT) Market will grow at a CAGR of 7.4% by forecast.
The major players operating in the Middle East Molecular Point of Care Testing (using NAAT) Market are SD Biosensor, Inc., Abbott, F.Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc, Meridian Bioscience, BD, Biomérieux Sa, Qiagen, Quidel Corporation, Bio-Rad Laboratories, Inc., GenMark Diagnostics, Seegene Inc., and Grifols S.A. among others.
On the basis of product, the Middle East Molecular Point of Care Testing (using NAAT) Market is segmented into Instruments and Consumables & Reagents.
The major countries covered in the Middle East Molecular Point of Care Testing (using NAAT) Market are Saudi Arabia, U.A.E, Israel, Egypt and the rest of Middle East.